NuPathe Inc. to Report Second Quarter 2011 Results and Hold Conference Call on Monday, August 15, 2011

CONSHOHOCKEN, PA--(Marketwire - August 10, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, will report second quarter 2011 results on Monday, August 15, 2011 after the close of the U.S. financial markets. NuPathe will also host a conference call at 4:30 p.m. EDT on the same day to discuss the second quarter 2011 financial results and recent operational highlights. A question and answer session will follow NuPathe’s remarks.

To participate on the live call, please dial 877-852-6583 (domestic) or +1-719-325-4779 (international), and provide the participant passcode 8545817 five to ten minutes ahead of the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 8545817.

A live audio webcast of the call will be also available via the “Investor Relations” page of the NuPathe website, www.nupathe.com. Please log on through NuPathe’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will be archived on NuPathe’s website for 90 days following the call.

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe’s lead product candidate, NP101 (also known as Zelrix), is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson’s disease, which the company plans to partner, and NP202 in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.